Adenocarcinoma of the gastroesophageal junction: Influence of esophageal resection margin and operative approach on outcome Journal Article
| Authors: | Barbour, A. P.; Rizk, N. P.; Gonen, M.; Tang, L.; Bains, M. S.; Rusch, V. W.; Coit, D. G.; Brennan, M. F. |
| Article Title: | Adenocarcinoma of the gastroesophageal junction: Influence of esophageal resection margin and operative approach on outcome |
| Abstract: | OBJECTIVE: To determine whether the length of esophageal resection or the operative approach influences outcome for patients with adenocarcinoma of the gastroesophageal junction (GEJ). SUMMARY BACKGROUND DATA: While R0 resection remains the mainstay of curative treatment of patients with GEJ cancer, the optimal length of esophageal resection remains controversial. METHODS: Patients with Siewert I, II, or III adenocarcinoma who underwent complete gross resection without neoadjuvant therapy were identified from a prospectively maintained database. Proximal margin lengths were recorded ex vivo as the distance from the gross tumor edge to the esophageal transection line. Operative approaches were grouped into gastrectomy (limited esophagectomy) or esophagectomy (extended esophagectomy). RESULTS: From 1985 through 2003, 505 patients underwent R0/R1 gastrectomy (n = 153) or esophagectomy (n = 352) without neoadjuvant treatment. There were no differences in R1 resection rate, number of nodes examined or operative mortality between gastrectomy and esophagectomy. Univariate analysis found >3.8 cm to be the ex vivo proximal margin length (approximately 5 cm in situ) most predictive of improved survival. Multivariable analysis in patients who underwent R0 resection with ≥15 lymph nodes examined (n = 275) found the number of positive lymph nodes, T stage, tumor grade, and ex vivo proximal margin length >3.8 cm to be independent prognostic factors. Subset analysis found that the benefit associated with >3.8 cm margin was limited to patients with T2 or greater tumors and ≤6 positive lymph nodes. CONCLUSIONS: In patients not receiving neoadjuvant therapy, the goal for patients with adenocarcinoma of the GEJ should be R0 resection including at least 15 lymph nodes, preferably with 5 cm of grossly normal in situ proximal esophagus for those with ≤6 positive lymph nodes. The operative approach may be individualized to achieve these goals. © 2007 Lippincott Williams & Wilkins, Inc. |
| Keywords: | adult; cancer survival; controlled study; treatment outcome; aged; aged, 80 and over; middle aged; cancer surgery; surgical technique; survival rate; major clinical study; cancer adjuvant therapy; follow-up studies; lymph node metastasis; neoplasm staging; prospective study; prospective studies; adenocarcinoma; surgical approach; prediction; disease severity; esophagus resection; gastrectomy; surgical mortality; multivariate analysis; medical documentation; univariate analysis; esophageal neoplasms; esophagectomy; lower esophagus sphincter; esophagogastric junction |
| Journal Title: | Annals of Surgery |
| Volume: | 246 |
| Issue: | 1 |
| ISSN: | 0003-4932 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2007-07-01 |
| Start Page: | 1 |
| End Page: | 8 |
| Language: | English |
| DOI: | 10.1097/01.sla.0000255563.65157.d2 |
| PUBMED: | 17592282 |
| PROVIDER: | scopus |
| PMCID: | PMC1899203 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 42" - "Export Date: 17 November 2011" - "CODEN: ANSUA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work